Global brokerage firm Jefferies has upgraded Zydus Lifesciences to a ‘Buy’ rating, citing the strength of the company’s US pipeline as a major growth driver. Jefferies raised its target price to Rs 1,450 from Rs 1,210, indicating a 30% upside from the previous closing price of Rs 1,113.80.
Sebi imposes Rs 10 lakh fine on Anand Rathi for violation of stock brokers’ norms
India’s market regulator Sebi fined Anand Rathi Share and Stock Brokers ₹10 lakh after inspections found multiple regulatory violations, including delayed glitch reporting, excessive capacity